Unlock instant, AI-driven research and patent intelligence for your innovation.

Long-chain non-coding RNA for diagnosing cisplatin resistance of triple negative breast cancer and application of long-chain non-coding RNA

A triple-negative breast cancer, long-chain non-coding technology, applied in the field of tumor molecular biology, can solve the problem of high sensitivity of triple-negative breast cancer tumor cells, achieve the effect of improving treatment effect, avoiding waste, and avoiding side effects

Active Publication Date: 2021-08-03
SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

BRCA1 / 2 mutation tumors can also cause triple-negative breast cancer tumor cells to be more sensitive to DNA double-strand break drugs, such as cisplatin and other platinum-based drugs, so that platinum-based drugs may become effective therapeutic drugs; that is, prior art There is a detection and diagnosis method that can predict the effectiveness of cisplatin drug treatment in triple-negative breast cancer-BRCA1 / 2 mutation
However, it does not mean that breast cancer without BRCA1 / 2 mutations is resistant to cisplatin therapy, and BRCA1 / 2 mutation detection to predict the effectiveness of cisplatin therapy in breast cancer is not necessarily applicable to all patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long-chain non-coding RNA for diagnosing cisplatin resistance of triple negative breast cancer and application of long-chain non-coding RNA
  • Long-chain non-coding RNA for diagnosing cisplatin resistance of triple negative breast cancer and application of long-chain non-coding RNA
  • Long-chain non-coding RNA for diagnosing cisplatin resistance of triple negative breast cancer and application of long-chain non-coding RNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Screening of long non-coding RNA LINC01778 V2

[0038] Cisplatin drugs were used for induction to establish stable cell lines of triple-negative breast cancer resistant to cisplatin drugs. In this example, a stable drug-resistant cell line of triple-negative breast cancer that is completely resistant to cisplatin was established by using the concentration gradient method, starting from a low concentration, and after two years. Then, through lncRNA chip detection, compare cisplatin-resistant triple-negative breast cancer cell lines and cisplatin-sensitive triple-negative breast cancer cell lines, and screen out a batch of differentially expressed lncRNAs; Cisplatin is not resistant to drugs; specifically, BGI sequencing is used to accurately screen lncRNA high-throughput sequencing based on Illumina's fourth-generation high-throughput sequencing platform. lncRNA high-throughput sequencing includes lncRNA identification, lncRNA quantification and differential analysis, ln...

Embodiment 2

[0040] Sequence analysis of the screened long non-coding RNA LINC01778 V2 using RACE

[0041] RACE (Rapid Amplification of cDNA Ends) is a technique for obtaining the full-length sequence of RNA transcripts. The 5' end (5' RACE-PCR) or 3' end (3' RACE-PCR) sequence of the transcript can be obtained based on a short known sequence in the transcript using RACE technology. In this example, the unknown sequence at the end of the long non-coding RNA (Long non-coding RNA, LncRNA) was amplified by the SMARTer RACE method (patented technology of clontech company).

[0042] Specifically include the following steps:

[0043] 1. Extraction of total RNA from cisplatin-resistant breast cancer cells

[0044] Promega's total RNA extraction kit (SV Total RNA Isolation System Start-Up Kit) is used to efficiently and quickly remove genomic DNA from cell samples by using improved recombinant DNase I, and to separate, purify and enrich DNA including long non Total RNA including coding RNA.

...

Embodiment 3

[0053] Prediction of the secondary structure of LINC01778 V2 using structure prediction software

[0054] After obtaining the full-length sequence of LINC01778 V2 based on the RACE experiment in Example 2, the RNA secondary structure of LINC01778 V2 was predicted using the Mfold and RNAfold software packages, and the results are as follows image 3 As shown, LINC01778 V2 has a stem-loop structure.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a long-chain non-coding RNA for diagnosing the cisplatin resistance of triple negative breast cancer and application thereof, for the first time, the sequence of LINC01778V2 differentially expressed in cisplatin-resistant triple negative breast cancer and cisplatin-sensitive triple negative breast cancer is cloned, and a foundation is laid for further researching the function of the long-chain non-coding RNA in the generation and development of cisplatin resistance of triple negative breast cancer. The LINC01778 V2 has high expression in the cis-platinum drug-resistant triple negative breast cancer and low expression in the cis-platinum sensitive triple negative breast cancer, the LINC01778 V2 can exist as a diagnostic marker, and whether the triple negative breast cancer is resistant to the cis-platinum drug or not can be diagnosed by detecting the expression level of the LINC01778 V2, so that targeted treatment is conveniently realized, the treatment effect is improved, and the lifetime of a patient is prolonged. And the expression is significantly related to cisplatin drug resistance, so that the invention also discloses application of the long-chain non-coding RNA in preparation of products for treatment of triple negative breast cancer, cisplatin treatment prediction and cisplatin treatment prognosis.

Description

technical field [0001] The present invention relates to the field of tumor molecular biology, and more specifically, relates to a long-chain non-coding RNA for cisplatin-resistant diagnosis of triple-negative breast cancer and its application. Background technique [0002] Triple negative breast cancer (TNBC) is a special molecular subtype of breast cancer, accounting for about 15% of breast cancer patients. The prognosis of TNBC patients is poor, and its pathological characteristics are high degree of malignancy, early age of onset, and early metastasis to internal organs and bones. TNBC lacks expression of ER (estrogen receptor), PR (progesterone receptor) and HER2 (epidermal growth factor receptor-2 gene), and common breast cancer treatments, including hormone therapy, often target these Two hormone receptors and the HER gene, so this type of therapy is generally not effective for patients with triple-negative breast cancer. Currently, chemotherapy is still the main sys...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/113C12Q1/6886
CPCC12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 姚燕丹李舜颖黄松音
Owner SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV